Skip to Main Content

Apathy in Dementia Methylphenidate Trial 2 (ADMET2)

Conditions

Alzheimer's Disease

Phase III

What is the purpose of this trial?

Visit the Alzheimer's Disease Research Unit (ADRU) here.

Apathy in Dementia Methylphenidate Trial 2 (ADMET 2) is a Phase III, placebo-controlled, masked, 6 month, 10-center randomized clinical trial sponsored by National Institutes of Aging involving 200 participants with Alzheimer's disease (AD). ADMET 2 is designed to examine the efficacy and safety of methylphenidate as treatment for clinically significant apathy in AD participants. ADMET 2 will enroll participants from real world settings such as outpatient, nursing home, and assisted living facilities and will examine the effects of methylphenidate on apathy and cognition. ADMET 2 will also conduct careful safety monitoring.

  • Trial with
    Johns Hopkins University
  • Start Date
    10/08/2015
  • End Date
    08/30/2019
Trial Image

For more information about this study, contact:

Carol Gunnoud

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8348

  • Last Updated
    02/22/2018
  • Study HIC
    #1503015481